Inactive Instrument

Sanofi SA Stock Nyse

Equities

US80105N1054

Pharmaceuticals

Sales 2024 * 46.11B 49.3B Sales 2025 * 49.91B 53.37B Capitalization 114B 122B
Net income 2024 * 6.8B 7.27B Net income 2025 * 8.62B 9.22B EV / Sales 2024 * 2.58 x
Net Debt 2024 * 5.22B 5.58B Net Debt 2025 * 2.36B 2.52B EV / Sales 2025 * 2.33 x
P/E ratio 2024 *
16.5 x
P/E ratio 2025 *
13.3 x
Employees -
Yield 2024 *
4.17%
Yield 2025 *
4.46%
Free-Float 87.01%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 39 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 62 20-04-27
Director/Board Member 64 20-05-21
More insiders
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company